Design of aerosolized amphotericin B formulations for prophylaxis trials among lung transplant recipients

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 4, 2004, Pages

  Perfect, John R ^a   Ashley, Elizabeth Dodds ^a   Drew, Richard ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE;

AEROSOL; ANTIFUNGAL PROPHYLAXIS; ARTICLE; ASPERGILLUS; CANDIDA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFECTION PREVENTION; LUNG TRANSPLANTATION; METHODOLOGY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS;

AEROSOLS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CLINICAL TRIALS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; HUMANS; IMMUNOCOMPROMISED HOST; LUNG TRANSPLANTATION; MYCOSES; PREVENTIVE MEDICINE; RESEARCH DESIGN; TRANSPLANTATION;

EID: 12844284520     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421958     Document Type: Article

References (22)

1. Bertocchi M, Thevenet F, Bastien O. Fungal infections in lung transplant recipients. Transplant Proc 1995; 27:1695.
2. Dauber J, Paradis I, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990; 11:291-308.
3. Horvath JA, Dummer S, Lloyd J, Walker B, Merrill W, Fritsch W. Infection in the transplanted and native lung after single lung transplantation. Chest 1993; 104:681-5.
4. Kanj SS, Welty-Wolf K, Madden J. Fungal infections in lung and heart-lung transplant recipients. Medicine (Baltimore) 1996; 75:142-56.
5. Ruffine E, Baldi S, Rapellino M, et al. Fungal infections in lung transplantation: incidence, risk factors, and prognostic significance. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:181-90.
6. Calvo V, Borro J, Morales P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999; 115:1301-4.
7. Dubois J, Bartter T, Gryn J, Pratter M. The physiologic effects of inhaled amphotericin B. Chest 1995; 108:750-3.
8. Reichenspurner H, Gamberg P, Nitschke M. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29:627-8.
9. Lazariashvilli N, Milston A, Barnes J, Dummer S. Survey of fungal management in lung transplantation [abstract 342]. Infectious Diseases Society of America, Chicago, 2002.
10. Behre G, Schwartz S, Lenz K. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995; 71:287-91.
11. Beyer J, Barzen G, Risse G. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1993; 37:1367-9.
12. Conneally E, Cafferkey M, Daly P, Keane CT, McCarthy LR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5:403-6.
13. Erjavec Z, Woolthuis G, Vries-Hospers H. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997; 16:364-8.
14. Hertenstein B, Stefanic M, Novotny J, et al. Low incidence of invasive fungal infections after bone-marrow transplantation in patients receiving amphotericin-B inhalations during neutropenia. Ann Hematol 1994; 68:21-6.
15. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20:1274-81.
16. Myers S, Devine S, Topper R. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 1992; 8:229-33.
17. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72:545-8.
18. Schwartz S, Behre G, Heinemann V. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia. Blood 1999; 93:3654-61.
19. Gryn J, Goldberg J, Johnson E, Siegel J, Inzerillo J. The toxicity of daily inhaled amphotericin B. Am J Clin Oncol 1993; 16:43-6.
20. Allen SD, Sorensen KN, Nejdl MJ, Proffit RT. Prophylactic efficacy of aerosolized liposomal (Ambisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrobial Chemother 1994; 34:1001-13.
21. Cicogna C, White M, Bernard E. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41:259-61.
22. Drew RH, Dodds AE, Benjamin DK Jr, Davis DR, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77:232-7.